Moreover, treatment with the anti‐RANKL/PD‐1 BsAb (200 μg) significantly improved s.c. tumor control compared with an equivalent overall antibody dose (200 μg) of anti‐RANKL plus anti‐PD‐1 (**P < 0.01 for both 3LL and CT26 models; Figure 3a, b). The gene discussed is PDCD1; the disease is neoplasm.